ArticleClinical pharmacology and therapeutics2026
Reply to "Understanding the Assumptions on Anifrolumab Dose Regimen Selection for a Phase 3 Trial in Lupus Nephritis".
Joachim Almquist et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.